Eli Lilly has once again lifted its expectations for the year, and the reason is no secret: demand for its weight-loss and diabetes injections keeps growing faster than almost anyone predicted. The Indianapolis-based drugmaker now expects full-year 2026 revenue of $91 billion to $92 billion, up from its previous range of $85 billion to $87 billion.
Third-quarter revenue rose 39% to $24.4 billion, comfortably ahead of the roughly $22.6 billion analysts had expected, according to LSEG data cited by Reuters. Mounjaro, the company’s diabetes medicine, brought in $10.72 billion worldwide, a jump of 65%. Its sister product Zepbound, sold for obesity, added $5.35 billion. Together the two tirzepatide brands generated around $16.1 billion in a single quarter.
Growth was driven by volume rather than price. Lilly said sales volume rose 53% while realised prices fell 15%, reflecting pressure on what patients and insurers pay. Outside the United States, Mounjaro sales nearly doubled, climbing 93%, and the company said its share of the international incretin market reached 58%.
There was one twist for investors. Despite the bigger revenue forecast, Lilly trimmed its adjusted profit outlook to $35 to $36 per share. The company explained that $4.57 per share in acquired research charges, mainly from its purchases of AtaiBeckley and Curevo, more than offset a $4.07 improvement in underlying earnings. The quarter also included about $900 million in one-off benefits, among them a final $410 million milestone payment linked to the diabetes drug Jardiance.
The broader picture is just as strong. Lilly said US prescriptions in the incretin obesity market grew 82%, with its medicines accounting for six out of ten of them, and research and development spending rose 23% to $4.2 billion in the quarter.
For now, Lilly’s lead in the booming GLP-1 market over rival Novo Nordisk looks firm, and the company has said it will present its 2027 guidance in January.





